Anavex Life Sciences has recently announced compelling results from a Phase 2b/3 trial investigating
their investigational therapy, blarcamesine, for early Alzheimer’s disease
(AD). The study demonstrated significant reductions in pathological amyloid-ß
levels and a slowing of brain atrophy in patients treated with blarcamesine.
Conducted across 52 medical research centers in five countries, the trial enrolled 508 participants
with early symptomatic AD. Patients were randomized to receive either
blarcamesine or a placebo for 48 weeks. The primary endpoints of cognitive and
functional efficacy were assessed using the Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-Cog) and the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living (ADCS-ADL) subscales.
The data revealed that blarcamesine-treated patients exhibited significant increases in validated
biomarkers of amyloid-ß pathology. Notably, the plasma Aβ42/40 ratio showed a
substantial improvement (P = .048), underscoring the agent’s robust antiamyloid
effect. MRI scans of the brain further confirmed a significant reduction in
brain volume loss among those on blarcamesine (P = .0005), compared to the placebo group.
Anavex’s findings are particularly significant given that blarcamesine is one of the first
therapies to demonstrate efficacy on biomarkers of neurodegeneration,
potentially slowing cognitive decline in AD patients. Marwan Noel Sabbagh, MD,
emphasized the importance of these results, noting the potential of
blarcamesine as a small oral molecule offering clinical benefits in cognition and neurodegeneration.
Safety data from the trial was also promising. Dizziness was the most common adverse event,
affecting 35.8% of participants during titration and 25.2% during maintenance,
but it was mostly mild to moderate in severity.
Christopher U Missling, PhD, CEO of Anavex Life Sciences, expressed optimism about the future of blarcamesine.
The promising results from this trial position Anavex at the forefront of
developing new, convenient treatments for Alzheimer’s disease. As the company
looks forward to advancing blarcamesine, the medical community and patients
alike have much to anticipate.
Anavex Life Sciences continues to make strides in the field of neurodegeneration, with
blarcamesine showcasing the potential to be a groundbreaking therapy for
Alzheimer’s disease. See related link for more information.
Learn more about Anavex on https://www.marketwatch.com/investing/stock/avxl